secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001437749-23-001990
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics receives Nasdaq minimum bid price deficiency notice
-----------------------------------------------------------------------

- Received Nasdaq notice on Jan 23, 2023; common stock bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days (until July 24, 2023) to regain compliance by closing bid price >= $1.00 for 10 consecutive days.
- If not compliant, may apply for additional 180-day period; reverse stock split is a potential cure.
- No immediate effect on listing; company monitoring and evaluating options to regain compliance.
- Failure to regain compliance could lead to delisting from the Nasdaq Global Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923001990/0001437749-23-001990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923001990/sabs20230123_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-001990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer